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Abstract
Introduction: Cyclooxygenase-2 (COX-2) is frequently over-expressed in primary breast cancer. In transgenic breast
cancer models, over-expression of COX-2 leads to tumour formation while COX-2 inhibition exerts anti-tumour
effects in breast cancer cell lines. To further determine the effect of COX-2 inhibition in primary breast cancer, we
aimed to identify transcriptional changes in breast cancer tissues of patients treated with the selective COX-2
inhibitor celecoxib.
Methods: In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to
receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according
to the same schedule (n = 15). Gene expression in fresh-frozen pre-surgical biopsies (before treatment) and surgical
excision specimens (after treatment) was profiled by using Affymetrix arrays. Differentially expressed genes and
altered pathways were bioinformatically identified. Expression of selected genes was validated by quantitative PCR
(qPCR). Immunohistochemical protein expression analyses of the proliferation marker Ki-67, the apoptosis marker
cleaved caspase-3 and the neo-angiogenesis marker CD34 served to evaluate biological response.
Results: We identified 972 and 586 significantly up- and down-regulated genes, respectively, in celecoxib-treated
specimens. Significant expression changes in six out of eight genes could be validated by qPCR. Pathway analyses
revealed over-representation of deregulated genes in the networks of proliferation, cell cycle, extracellular matrix
biology, and inflammatory immune response. The Ki-67 mean change relative to baseline was -29.1% (P = 0.019)
and -8.2% (P = 0.384) in the treatment and control arm, respectively. Between treatment groups, the change in
Ki-67 was statistically significant (P = 0.029). Cleaved caspase-3 and CD34 expression were not significantly different
between the celecoxib-treated and placebo-treated groups.
Conclusions: Short-term COX-2 inhibition by celecoxib induces transcriptional programs supporting anti-tumour
activity in primary breast cancer tissue. The impact on proliferation-associated genes is reflected by a reduction of
Ki-67 positive cells. Therefore, COX-2 inhibition should be considered as a treatment strategy for further clinical
testing in primary breast cancer.
Trial registration: ClinicalTrials.gov NCT01695226.
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Introduction
Cancer development is associated with chronic immune
activation, but the mechanisms behind this observation
are not fully understood [1,2]. In addition, the inflamma-
tory processes that follow tumour formation provide a
microenvironment in which the development of malignant
disease may be enhanced [3]. The involvement of chronic
immune activation has been supported by several lines of
evidence in which an association between non-steroidal
anti-inflammatory drug (NSAID) consumption and
decreased risk of cancer development, including breast
cancer, has been demonstrated [4-11]. However, the exact
mechanisms by which NSAIDs exert inhibiting effects on
tumour development have not yet been completely
elucidated.
Mediators of inflammatory responses, such as the
cyclooxygenase (COX)-derived prostaglandins (PG), play
an important role in tumour formation and provide a tar-
get for therapeutic intervention [3]. PGs have important
functions in every organ system and regulate a variety of
physiological functions, such as immunity, maintenance of
vascular integrity and bone metabolism [12]. Elevated
COX expression in breast cancer was first suggested by
the finding of elevated PG production in breast cancer
cells [13]. To date, two different COX genes have been
characterised, COX-1 and COX-2. COX-1 is constitutively
expressed by almost all human cells and, therefore, differs
from COX-2 expression which is normally absent but is
inducible by a wide spectrum of growth factors, pro-
inflammatory cytokines [14,15] and tumour-promoting
compounds [16,17]. Consistently, COX-2 is abundantly
expressed in breast cancer tissue [18] and its enforced
over-expression in mammary gland epithelia of transgenic
mice results in breast tumour development [19], suggest-
ing that COX-2 might be an interesting therapeutic target
in breast cancer.
While several pre-clinical studies have indeed shown
anti-tumour capacities of COX-2 inhibition, the treatment
effects on primary breast cancer in the clinical setting
remain elusive. Therefore, we aimed to determine for the
first time transcriptional changes in primary breast cancer
tissue of women with early breast cancer after treatment
with the selective COX-2 inhibitor celecoxib. In our ran-
domised controlled trial we found that upon celecoxib
treatment numerous genes are differentially expressed in
breast cancer tissues with an overall anti-tumour activity,
suggesting that COX-2 inhibition should be further con-
sidered for clinical testing as a treatment option in breast
cancer.
Methods
Patients and study design
The study was a double-blind, randomised, placebo-
controlled phase II pre-surgical trial of celecoxib in early
breast cancer. Exclusion criteria were: HIV, hepatitis B
virus (HBV) or hepatitis C virus (HCV) positivity, known
hypersensitivity to NSAIDs, patients already using NSAIDs
or systemic use of corticosteroids. Informed consent was
obtained prior to entering the trial and the Medical Ethics
Committee of the Maastricht University Medical Centre+
(MUMC+) approved the study. We estimated that to test
18,500 genes at the 5% significance level and ensure 80%
power, 23 samples were needed to detect differentially
expressed genes by t-tests with a fold change of at least 1.5
(http://bioinformatics.mdanderson.org/MicroarraySample-
Size/). Initially, 45 patients were recruited between 2005
and 2007 and randomly allocated 2:1 to the treatment (n =
30) or placebo group (n = 15). Celecoxib was pre-surgi-
cally administered for two to three weeks at 400 mg twice
daily, whereas patients in the control arm received a pla-
cebo on the same schedule. Eight patients allocated to the
treatment arm dropped out because these patients were
operated earlier, thus drug compliance was insufficient
(Figure 1). Tumour histology was assessed according to
criteria defined by the World Health Organization (WHO)
[20], while staging was performed according to the Union
for International Cancer Control (UICC) criteria [21].
Tumours were graded following the system of Bloom and
Richardson, as modified by Elston and Ellis [22]. Patient
characteristics are described in Table 1. Importantly, in
our study design patients acted as their own control, with
Figure 1 Flow diagram of the presented study. The design is a
double-blind, randomised, controlled phase II trial of pre-operative
celecoxib versus placebo in early breast cancer. Note that eight
patients had discontinued intervention in the treatment arm. Gene
expression profiling (GEP) has been performed from samples where
indicated.
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a direct comparison of the final surgical specimen with the
initial diagnostic biopsy. The inclusion of a placebo group
served to observe a possible confounding impact of the
disease and the experimental procedure, thereby allowing
determination of a differential impact of celecoxib only.
Biopsy method
Before patient allocation to the groups, two to three
core needle biopsies from the centre of the primary
tumour were obtained using a 14-gauge needle under
ultrasound guidance. At surgery, a central sample of the
excised tumour was obtained. One part of the biopsies
and surgical excision specimens was snap-frozen in
liquid nitrogen within 30 minutes after removal and
stored at -80°C until use, while the remaining part was
formalin-fixed and paraffin-embedded (FFPE). All speci-
mens subjected to gene expression analyses had a
tumour cellularity of at least 80%, as determined by hae-
matoxylin and eosin stained sections.
RNA isolation, cRNA production and fragmentation, array
hybridisation and scanning
After homogenisation of fresh-frozen tissue specimens,
total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s pro-
tocol. DNase treatment was performed with the RNase-
Free DNase Set (Qiagen, Hilden, Germany) followed by
purification of the RNA samples using the RNeasy Mini-
kit (Qiagen). RNA quantity and purity were determined
spectrophotometrically using the Nanodrop ND-1000
(Nanodrop Technologies, Wilmington, DE, USA) and
RNA integrity was assessed by determining the RNA
28S/18S ratio using the Bioanalyzer 2100 (Agilent Tech-
nologies, Santa Clara, CA, USA). Biotinylated aRNA was
synthesised and fragmented using the GeneChip IVT
Express Kit from Affymetrix (Santa Clara, CA, USA).
Hybridisation to Affymetrix Human Genome U133 Plus
2.0 arrays and subsequent scanning was performed fol-
lowing the manufacturer’s guidelines using the GeneChip
scanner 3000 (Affymetrix). Microarray datasets are pub-
licly available at ArrayExpress database [23] under acces-
sion number E-MTAB-566.
Microarray data analysis
Images of the arrays were quantified with GCOS software
(Affymetrix). The chip description file (CDF) used for the
analysis was an update created and freely distributed by
the microarray lab of the University of Michigan [24]
based on Ensembl (version 10). The treatment effects on
global gene expression were assessed by microarray ana-
lyses of subjects after celecoxib treatment versus subjects
before treatment and controls (before and after treat-
ment). Thus, expression changes have been adjusted for
differences in the pre- and post-treatment specimens of
the control group. The genes were analysed using a
Gaussian linear regression including the hybridisation
and labelling spikes and COX-2. The inference criterion
used for comparing the models is their ability to predict
the observed data, that is, models are compared directly
through their minimised minus log-likelihood. When the
numbers of parameters in models differ, they are pena-
lised by adding the number of estimated parameters, a
form of the Akaike information criterion (AIC) [25]. For
each gene, the group effect only after intervention was
then added to the model. The gene under consideration
was found to be differentially expressed if the AIC
decreased compared to the model not containing this
effect. All statistical analyses presented were performed
using the freely available program R [26] and the publicly
available library ‘growth’ [27].
Validation of microarrays by quantitative RT-PCR
Quantitative RT-PCR (qPCR) was performed for
selected genes on all 74 samples in order to validate the
Table 1 Clinico-pathological characteristics of breast
cancer patients.
Variable Categorisation Control Celecoxib
Number = 15 Number = 22
Mean age ± SD (years)a 57 ± 12 51 ± 12
Histological tumour typeb
Invasive ductal carcinoma 13 (87%) 19 (86%)
Invasive lobular carcinoma 2 (13%) 3 (14%)
Tumour sizec
pT1 10 (67%) 8 (36%)
pT2 5 (33%) 13 (59%)
pT3 0 (0%) 1 (5%)
Lymph node statusc
Negative (pN0) 11 (73%) 10 (45%)
Positive (pN1-3) 4 (27%) 12 (55%)
Tumour graded
G1 5 (33%) 1 (5%)
G2 4 (27%) 7 (32%)
G3 6 (40%) 14 (63%)
Oestrogen receptor statuse
ER positive 11 (73%) 19 (86%)
ER negative 4 (27%) 3 (14%)
Progesterone receptor statuse
PgR positive 10 (67%) 17 (77%)
PgR negative 5 (33%) 5 (23%)
HER2 statusf
HER2 positive 3 (20%) 3 (14%)
HER2 negative 12 (80%) 18 (82%)
Unknown 0 (0%) 1 (5%)
aAt time of diagnosis; baccording to Tavassoli and Devilee [20]; caccording to
Sobin and Wittekind [21]; daccording to Elston and Ellis [22]; epositivity
defined as > 10% positive cells as analysed by immunohistochemistry [60];
fpositivity defined by immunohistochemistry (score 3+) or by dual-color FISH.
Percentages may not sum-up to 100 due to rounding. FISH, fluorescence in
situ hybridisation.
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results obtained in the microarray study. As a reference,
TATA box binding protein (TBP) and RNA, 18S riboso-
mal 1 (RN18S1) were included as housekeeping genes.
The list of genes and the primers that were used are
described in Additional file 1, Table S1. Excess biotiny-
lated aRNA (before the fragmentation step) was used for
validation, after cDNA synthesis with M-MuLV Reverse
Transcriptase (Finnzymes, Espoo, Finland) and oligo
(dT), (Invitrogen) using the SensiMix SYBR Kit (Quan-
tace, London, UK) following the manufacturer’s proto-
col. qPCRs were run on the 7900HT system (Applied
Biosystems, Singapore). Results were analysed using a
Gaussian linear regression similar to microarray data.
Expression of housekeeping genes (TBP and GAPDH)
and COX-2 were included during the analysis. The AIC
was used to assess whether there was a difference
between the controls and patients (group effect).
Analysis of functional categories
Significantly altered genes that were found to have a fold-
change difference of at least 10% were classified into cate-
gories of biological processes and molecular functions
using DAVID (Database for Annotation, Visualisation and
Integrated Discovery) [28] and PathVisio [29]. DAVID and
PathVisio analyses for pathway enrichment were per-
formed first for all significantly altered genes, then for up-
and down-regulated genes separately. DAVID results are
listed together with P-values corrected with the Bonferroni
method, as this was the most conservative method used by
the software. A P-value of 0.05 was used as a cut-off value.
In both analyses we filtered the pathways or gene ontology
(GO) terms for which less than five and more than 150
genes were found, as those were either too specific or too
general for our analysis. In PathVisio, the gene database
Hs_Derby_20110601.bridge and the pathway collection
from WikiPathways [30] were used to obtain a ranked list
of pathways with differentially expressed genes. PathVisio
results were sorted by Z-score, which is the standard sta-
tistical test under the hypergeometric distribution. Only
pathways with a Z-score above 3, which corresponds to
P-values of 0.0013 or lower, were selected.
Tissue marker expression
Biomarkers of response were assessed by immunohisto-
chemistry on FFPE tissues. Cell proliferation was assessed
using the MIB1 mouse monoclonal antibody to Ki-67 [31].
Measurement of apoptosis was performed by cleaved cas-
pase-3 (Asp175) staining [32]. Tumour cells/section were
counted for Ki-67 (1,000 cells) and apoptotic index (3,000
cells). The apoptotic index was expressed as a percentage
of the number of cells displaying apoptotic bodies, scoring
0 if < 0.5%, +1 if between 0.5% and 2%, and +3 if > 2%.
Samples were also assessed for expression of CD34 [33]
using the Chalkley method [34].
Statistical analyses
Ki-67 values at baseline and time of surgery were
expressed as geometric mean proportions of the baseline
and transformed into percentage changes. Ki-67 changes
within groups were compared using a paired t-test, differ-
ences in Ki-67 and CD34 between groups by using an
unpaired t-test, and the Mann-Whitney test was used for
group comparisons. Differences in caspase-3 expression
were assessed by the Freeman-Halton extension of the
Fisher’s exact probability test. All tests were performed
two-sided at the 5% significance level.
Results
Celecoxib treatment changes gene expression in breast
carcinoma tissue
Two to three weeks of celecoxib treatment significantly
altered the expression of 1,558 genes in breast cancer tis-
sues, of which 972 genes were up- and 586 genes were
down-regulated after treatment and adjustment to control
tissue gene expression. The 50 most strongly up-regulated
and down-regulated genes are presented in Additional
file 2, Table S2 and Additional file 3, Table S3, respec-
tively. For all of the selected genes, except two, significant
expression changes were confirmed by qPCR (Figure 2).
The list of the biological pathways, in which significantly
changed genes were over-represented, identified by
DAVID analysis, is shown in Table 2. Biological processes
identified by PathVisio are shown in Table 3. In both
approaches down-regulated genes were consistently over-
represented in cell cycle-related processes and prolifera-
tion. Up-regulated genes were over-represented in extra-
cellular matrix (ECM) organisation, cell adhesion, and
blood vessel development in DAVID analyses, whereas
PathVisio results suggested an implication of further
tumour suppressive pathways, for example, complement
Figure 2 qPCR validation of selected genes differentially
expressed in celecoxib-treated samples as determined by
microarray analysis. Fold-change and the 95% CI (error bars) are
shown. Expression of six out of eight genes analysed (indicated by
asterisks) was significantly changed in agreement with the
microarray analysis.
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Table 2 Over-represented functional categories within genes up- and/or down-regulated after celecoxib treatment
using DAVID.





0030198 Extracellular matrix organisation 28 4.657 6.35E-08
0009611 Response to wounding 70 2.337 1.32E-07
0007155 Cell adhesion 83 2.108 3.24E-07
0022610 Biological adhesion 83 2.105 3.46E-07
0001944 Vasculature development 43 2.951 1.20E-06
0001568 Blood vessel development 42 2.953 1.96E-06
0043062 Extracellular structure organisation 33 3.502 2.35E-06
0051270 Regulation of cell motion 34 3.047 4.89E-05
0001501 Skeletal system development 46 2.510 5.23E-05
0030334 Regulation of cell migration 31 3.173 9.15E-05
0040012 Regulation of locomotion 33 2.973 1.51E-04
0042127 Regulation of cell proliferation 83 1.834 2.27E-04
0042060 Wound healing 32 2.944 3.14E-04
0007160 Cell-matrix adhesion 20 3.931 1.42E-03
0048514 Blood vessel morphogenesis 33 2.692 1.56E-03
0031589 Cell-substrate adhesion 21 3.745 1.57E-03
0006928 Cell motion 53 1.984 7.97E-03
0001525 Angiogenesis 25 2.922 1.15E-02
0009612 Response to mechanical stimulus 14 4.324 3.91E-02
Down-regulated
0006259 DNA metabolic process 52 3.018 5.10E-09
0007049 Cell cycle 64 2.411 1.85E-07
0006260 DNA replication 28 4.387 3.98E-07
0022402 Cell cycle process 50 2.569 4.12E-06
0000278 Mitotic cell cycle 37 2.898 3.70E-05
0000279 M phase 32 2.832 6.92E-04
0051276 Chromosome organisation 40 2.461 7.18E-04
0006974 Response to DNA damage stimulus 34 2.656 1.20E-03
0000087 M phase of mitotic cell cycle 25 3.229 1.76E-03
0022613 Ribonucleoprotein complex biogenesis 22 3.544 2.07E-03
0000280 Nuclear division 24 3.156 4.53E-03
0007067 Mitosis 24 3.156 4.53E-03
0022403 Cell cycle phase 35 2.454 4.81E-03
0042254 Ribosome biogenesis 17 4.062 8.27E-03
0048285 Organelle fission 24 3.031 9.01E-03
0006281 DNA repair 27 2.785 9.53E-03
0006396 RNA processing 41 2.185 1.01E-02
0031396 Regulation of protein ubiquitination 15 4.434 1.30E-02
0031397 Negative regulation of protein ubiquitination 13 5.177 1.31E-02
0031145 Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic
process
12 5.461 2.01E-02
0016071 mRNA metabolic process 31 2.428 2.52E-02
0034470 ncRNA processing 20 3.133 4.28E-02
0051439 Regulation of ubiquitin-protein ligase activity during mitotic cell cycle 12 4.986 4.85E-02
aP-values shown were corrected for multiple testing using the Bonferroni method; categories ranked by P-value; functional categories with P-values < 0.05 and at
least five, but less than 150 genes meeting the criterion are shown.
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activation, senescence and autophagy, and transforming
growth factor-b (TGF-b) signaling.
Effects of celecoxib on cell cycle gene expression
DAVID and PathVisio consistently identified biological
processes referring to regulation of cell cycle and prolifera-
tion, in particular among those genes down-regulated after
treatment. An important downstream DNA damage
response gene, GADD45A (Growth arrest and DNA-
damage-inducible, alpha), was significantly up-regulated
(Figure 3). Consistent with a putative activation of the G2/
M checkpoint and cell cycle arrest due to DNA damage
response, target genes CCNB1 (G2/mitotic-specific cyclin-
B1) and CCNB2 (G2/mitotic-specific cyclin-B2) were sig-
nificantly down-regulated after treatment.
Effects of celecoxib on ECM degradation gene expression
The majority of the matrix metalloproteinase (MMP)
family members have been associated with tumour pro-
gression. The conversion of pro-MMP to active MMP-2
requires membrane type MT1-MMP (MMP-14), a
trans-membrane protein that is activated intracellularly
by the convertase FURIN [35]. The down-regulation of
the protein convertase FURIN in the celecoxib-treated
group potentially leads to less activation of MT1-MMP.
Additionally, the effect of MMP-2 on proteolysis was
inhibited either by up-regulation of TIMP1, TIMP2,
TIMP3, or by RECK (Figure 4). The up-regulated RECK
exerts inhibitory effects on the conversion of pro-MMP-
2 to MMP-2 and on the activation of pro-MMP-9 to
MMP-9. In summary, our data suggest that degradation
of ECM proteins was significantly inhibited in the cele-
coxib-treated group.
Recruitment of tumour-infiltrating leukocytes to breast
carcinoma tissue after celecoxib treatment
Breast cancer tissue of celecoxib-treated patients showed
a significantly increased expression of MHC class II
genes, including HLA-DRa and HLA-DRb2, CD74
(MHC class II invariant chain) and HLA-DM, but not
HLA-DQ and HLA-DOA [see Additional file 4, Table
S4]. MHC class I gene expression was not significantly
changed. Subsequent to the increased expression of
HLA-class II genes, co-stimulatory markers of antigen-
presenting cells (CD83) and the monocyte differentiation
antigen CD14 were up-regulated after celecoxib treatment.
Infiltration of antigen-presenting cells was supported by
increased expression of the Pattern Recognition Receptors
(PRR), Toll-like receptor-2 (TLR2) and MD-1 (LY86).
Gene expression of the classical B cell markers, CD20 and
CD19, was not altered, although there was increased
expression of immunoglobulin J chain. As myeloid-derived
suppressor cells (MDSC) immune suppressive cells also
express MHC class II molecules, and their presence corre-
lates with COX-2 over-expression [36], induction of
MDSC signalling was investigated. However, MDSC







Complement and coagulation cascades 15 50 30.00% 5.65
Senescence and autophagy 18 100 18.00% 3.61
RANKL/RANK signalling pathway 11 50 22.00% 3.58
Complement activation, classical pathway 5 15 33.33% 3.55
Matrix metalloproteinases 7 29 24.14% 3.14
TGF beta signalling pathway 18 113 15.93% 3.03
Inflammatory response pathway 7 30 23.33% 3.03
Oxidative stress 6 24 25.00% 3.01
Adipogenesis 19 125 15.20% 2.89
Endochondral ossification 11 61 18.03% 2.82
TWEAK signalling pathway 8 40 20.00% 2.73
SREBP signalling 6 28 21.43% 2.56
Down-regulated
Cell cycle 17 95 17.89% 6.62
DNA replication 9 41 21.95% 5.61
Nucleotide metabolism 5 17 29.41% 5.12
Proteasome degradation 10 57 17.54% 4.97
Electron transport chain 10 81 12.35% 3.61
G1 to S cell cycle control 7 67 10.45% 2.51
aZ-score is the standard statistical test under the hypergeometric distribution; pathways ranked by Z-score. Z-score > 1.96 (corresponding to P-value = 0.05) and
at least five, but less than 150 genes meeting the criterion are shown. TGF, tumour growth factor.
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induction seems unlikely, since the expression of MDSC-
signalling genes ARG1 and NOS2 is not altered. Moreover,
expression of important effector molecules, such as gran-
zymes and perforin, was not affected. The increased infil-
tration of leukocytes observed in the breast tumour seems
restricted to macrophages and dendritic cells.
Change of tissue biomarker expression
To confirm the transcriptional changes, we determined
expression of protein markers for proliferation, apoptosis,
and neo-angiogenesis. The proliferation marker Ki-67
was assessed on paired pre- and post-treatment tissues.
Due to a lack of further tissue, apoptotic marker cleaved
caspase-3 and neo-angiogenesis marker CD34 were
assessed only on post-treatment tissues. Baseline Ki-67
positivity in the control group (geometric mean: 10.0%;
95% CI: 5.5 to 18.3) was not significantly different from
baseline Ki-67 positivity in the treatment group (geo-
metric mean: 13.4%; 95% CI: 9.8 to 18.3) (P = 0.915). The
change in Ki-67 is shown for individual patients accord-
ing to treatment or control arm in Figure 5. The geo-
metric mean change in Ki-67 relative to baseline in the
treatment arm was -29.1% (95% CI: -40.1% to -16.2%, P =
0.019), whereas in the control arm it was -8.2% (95% CI:
Figure 3 Effects of celecoxib treatment on cell cycle and proliferation. Contributed map from GenMAPP software with an overview of the
pathways and genes involved in cell cycle regulation. The expression fold-changes of each gene are indicated next to the gene box. Genes
highlighted in red and green in the left box half represent genes with fold-changes increased and decreased, respectively. Red colour in the
right box half indicates a significant change. Grey boxes correspond to genes that were not analysed in the arrays.
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-23.1 to 9.5%, P = 0.384). There was a significant change
difference between the two groups (P = 0.029). In con-
trast, the apoptotic index was not significantly different
in post-treatment tissues (P = 0.231). The number of
CD34 positive cells was slightly higher in celecoxib-trea-
ted tissues, but this was statistically insignificant. The
geometric means (95% CI) of the ‘Chalkley mean’ value
were 6.8 (5.4 to 8.5) in the control group and 7.7 (6.8 to
8.8) in the treatment group (P = 0.376).
Discussion
In this study, we analysed the transcriptional changes
seen in primary breast cancer tissue following short-
term celecoxib treatment. To accomplish this, we used
global gene expression profiles from paired pre- and
post-treatment specimens. After adjustment to the con-
trol group, we identified a large number of differentially
expressed genes after treatment that are involved in the
regulation of cancer-associated pathways, such as cell
cycle and proliferation, ECM biology, and inflammatory
response, amongst others. Most convincingly, COX-2
inhibition induced gene expression patterns indicative of
a decelerated cell cycle and reduced proliferation. Cele-
coxib may induce G2/M arrest by p53 activation,
Figure 4 Effects of celecoxib treatment on extracellular matrix protein degradation. Map designed on GenMAPP software with an
overview of the genes involved in the extracellular matrix protein degradation process. The expression fold-changes of each gene are indicated
next to the gene box. Genes highlighted in red and green in the left box half represent genes with fold-changes increased and decreased,
respectively. Red colour in the right box half indicates a significant change. Grey boxes correspond to genes that were not analysed in the
arrays.
Figure 5 Effects of celecoxib treatment on Ki-67 protein
expression. (A) Examples of immunohistochemical staining of
nuclear Ki-67 protein on breast cancer tissues yielding a high score
(left) and low score (right). Scale bar = 100 μm. (B) Shown are the
Ki-67 scores from individual patients in the control arm (plot on left-
hand side) and treatment arm (plot on right-hand side). Geometric
means in the control group were statistically not different (P =
0.384), while the geometric mean after celecoxib treatment was
significantly reduced (P = 0.019). Also, the change of the means
between both groups was significantly greater in the celecoxib-
treated group (P = 0.029).
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leading to GADD45A up-regulation, which in turn inhi-
bits cyclin-B1 and cyclin-B2 expression and promotes
G2/M arrest (Figure 3). A G2/M arrest is mainly forced
after DNA damage to enable the initiation of DNA
repair mechanisms [37]. Our finding is in line with pre-
vious studies investigating the effects of celecoxib on
cancerous cells in vitro. Dvory-Sobol and colleagues
demonstrated that celecoxib induces G2/M arrest asso-
ciated with cyclin-B1 down-regulation in K-RAS-trans-
formed enterocytes [38], and in the COX-2 expressing
murine breast cancer cell line MCa-35, celecoxib
induced a G2/M arrest followed by apoptosis [39]. Inter-
estingly, equally treated lung cancer A549 cells lacking
COX-2 expression showed increased DNA damage, but
low levels of apoptosis in these cells suggested a selec-
tive effect of celecoxib on COX-2 expressing cells [39].
Celecoxib seems to increase DNA damage in irradiated
cells, enhancing their radiosensitivity [40]. However,
the mechanisms behind increased DNA damage in
celecoxib-treated tumour cells remains poorly understood.
Our results are further consistent with a study of colorec-
tal cancer (CRC) cell lines in which more than 1,000 genes
were identified as differentially expressed after celecoxib
treatment, clustering of which revealed significant changes
of cell cycle control, apoptosis, and lymphocyte infiltration
[41]. Also in a study on primary CRC, celecoxib-induced
gene expression changes significantly interfered with pro-
liferation pathways [42]. In summary, we have confirmed a
positive treatment effect of COX-2 inhibition on cell pro-
liferation-related transcriptional programs in primary
breast carcinomas, as has been previously demonstrated
by several in vitro and in vivo studies.
Disruption of the basement membrane is a hallmark of
malignancy. Degradative enzymes, such as MMPs, are pro-
duced by tumour cells and by resident and infiltrating cells
as a response to the tumour, and contribute to matrix
degradation and facilitate tumour invasion. MMP-2,
MMP-9, and other members of the MMP family have
been associated with tumour progression [43]. In particu-
lar, MMP-2 and MMP-9 activity appears to be inhibited
by celecoxib in our study, the first by up-regulation of
MMP antagonists (TIMP1, TIMP2, and TIMP3), the latter
by up-regulation of the MMP-9 inhibitor RECK. An invol-
vement of selective COX-2 inhibition in matrix stability by
decreasing MMP activity and tumour invasiveness has
been previously demonstrated in breast and CRC cancer
models [44,45], thus being in good agreement with our
data.
Several lines of evidence demonstrated that immune cell
infiltration in tumours is enhanced by celecoxib treatment,
which is associated with a better prognosis [46,47]. In our
study, increased infiltration of antigen-presenting cells is
supported by gene expression data whereas other immune
cells of both the innate and adaptive immune system do
not seem to be affected by celecoxib treatment. Most up-
regulated genes within this category belong to MHC class
II. Comparable data on MHC class I and II induction have
been reported by Lönnroth et al. in CRC patients using a
NSAID [47].
In order to investigate whether observed gene expres-
sion changes after COX-2 inhibition have translated to a
biologically relevant effect, we analysed protein markers
for proliferation, apoptosis, and neo-angiogenesis in pri-
mary tissues. Suppression of the proliferation marker
Ki-67 has been previously reported as a surrogate marker
for decreased aromatase activity in oestrogen receptor
(ER) positive breast cancer treated with aromatase inhibi-
tors (AI) for two weeks [48,49]. Since COX-2 expression is
positively correlated with tumour aromatase content [50],
we were interested whether COX-2 inhibition would also
lead to a reduction in Ki-67 positivity. As expected from
previous studies [51,52], Ki-67 was not significantly
reduced in the control arm. In contrast, the celecoxib arm
showed a significant suppression of Ki-67, confirming the
reduced proliferation observed in our gene expression
data and suggesting an indirect treatment effect on aroma-
tase activity. Although the Ki-67 suppressive effect was
only modest (-29%) as compared to the AI anastrozole
(-75%) [49], it was similar to the Ki-67 suppression
achieved with another AI, that is, raloxifene (-24%) [52].
Other than Ki-67, caspase-3 and CD34 were not signifi-
cantly changed after celecoxib treatment, although this has
to be interpreted cautiously due to the lack of baseline
data. However, in a previous neo-adjuvant study in breast
cancer, two weeks of celecoxib did not result in a biologi-
cal response of proliferation and apoptosis, as determined
by Ki-67 staining and TUNEL assays, respectively [53].
Notably, the referenced study analysed fewer patients and
used half the drug dose that we applied. Taken together,
we hypothesise that two weeks of COX-2 inhibition may
not be sufficient to translate all transcriptional activation
to a measurable biological phenotype. In particular, sup-
pression of blood vessel development may take effect only
after longer drug exposure, which should be taken into
consideration when designing future clinical trials of
COX-2 inhibition in cancer.
In breast cancer, COX-2 over-expression is positively
associated with HER2 over-expression [54] and with
tumour aromatase content [50]. Therefore, COX-2 inhibi-
tion might prove beneficial, especially in combination with
trastuzumab in HER2 positive breast cancer or with AI in
hormone receptor (HR) positive disease. In trastuzumab-
refractory metastatic breast cancer COX-2 inhibition was
previously shown to be inactive [55]. However, improved
efficacy and endpoint benefits of celecoxib in combination
with AI were reported in post-menopausal metastatic
breast cancer, although these were pronounced only in
tamoxifen resistant patients [56,57]. Although promising,
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further studies are needed in order to elucidate a clinical
benefit of COX-2 inhibition in combination with other
drugs in breast cancer treatment.
The strength of our study is the trial design, which
allows patients to act as their own control, and the
inclusion of a placebo group, which served to exclude
potentially confounding effects by the disease and the
experimental procedures. It would be interesting to sub-
analyse the gene expression and Ki-67 in stratified
breast cancer subtypes, as for example, HR positive ver-
sus negative disease, but this is hindered by the low
number of HR negative patients in the control (n = 5)
and the treatment arm (n = 1). Of note, however, there
is a trend of bias towards poorer prognostic factors in
the celecoxib arm, which could not have been predicted
or changed before the end of the treatment procedure.
Although this bias must be considered a limitation of
the study, we speculate that the observed anti-tumour
transcriptional response in this arm may have been
under-estimated, and thus could become even more evi-
dent by comparing clinically highly similar arms.
Unfortunately, eight patients dropped out of the study
due to early surgery, all of them from the treatment
arm, resulting in a reduced statistical power to detect
differentially expressed genes. However, in our microar-
ray analysis we found more differentially expressed
genes than expected by chance alone (1,558 observed
versus 920 expected). After identification of the differen-
tially expressed genes, pathway analyses were performed
in order to identify genes clustering within the same
biological pathway, as those genes are very likely to be
true positives.
Large meta-analyses have recently shown that the non-
selective COX inhibitor aspirin is protective against cancer
development. Regular intake of aspirin significantly
reduced the risk of several cancers, including breast cancer
(OR = 0.88) [58], and three years onwards of daily aspirin
intake reduced cancer incidence in both women and men
(OR = 0.75) [59]. These studies suggest that selective
COX-2 inhibitors may have similar effects on cancer inci-
dence albeit with the advantage of causing less adverse
side effects associated with aspirin use, such as gastroin-
testinal bleeding. COX-1 is expressed constitutively in
many different tissues, whereas COX-2 is conditionally
induced, such as in inflammation, suggesting that selective
COX-2 inhibition might prove more successful in cancer
prevention than non-selective COX inhibitors.
Conclusions
Our clinical trial provides substantial evidence for an anti-
tumour activity of celecoxib based on global transcriptional
changes and suppression of Ki-67 protein in primary breast
cancer tissues, encouraging further clinical trials of cele-
coxib or its derivative molecules in breast cancer. Our
study confirms results from previous in vitro and in vivo
studies as we found a large number of cell-cycle and prolif-
eration-associated genes to be differentially expressed in
celecoxib-treated primary breast cancer tissues. Our aim
was to determine the global transcriptional response to
short-term COX-2 inhibition in primary tumours, and our
results indicate that proliferation and ECM biology are sig-
nificantly influenced, possibly underlying the proposed
anti-tumour activity. Future trials of COX-2 inhibition con-
sidering other primary endpoints, such as pathological or
clinical response, should take into account that effects of a
transcriptional response may need a longer time to trans-
late into a measurable clinical benefit.
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